With the advent of DLL3-targeting agents and recent FDA approval of tarlatamab-dlle, a bispecific T-cell engager targeting DLL3 in ES-SCLC, additional investigation is warranted in EGFR-mutant NSCLC after HT. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.